This reasoning is supported by recent studies comparing EGFR-targeted and non-targeted scTRAIL on HCC, healthy human liver cells and intact liver tissue, revealing superior tolerability of the targeted molecule [47]. This evidence concerns the gene EGFR and hepatocellular carcinoma.